Acute kidney injury in patients treated with immune checkpoint inhibitors.

Autor:	Gupta S; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA sgupta21@bwh.harvard.edu., Short SAP; University of Vermont Larner College of Medicine, Burlington, Vermont, USA., Sise ME; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA., Prosek JM; Division of Nephrology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, Ohio, USA., Madhavan SM; Division of Nephrology, Department of Internal Medicine, The Ohio State University Medical Center, Columbus, Ohio, USA., Soler MJ; Nephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, Barcelona, Spain., Ostermann M; Department of Critical Care & Nephrology, King's College London, Guy's and St Thomas' Hospital, London, UK., Herrmann SM; Division of Nephrology & Hypertension, Mayo Clinic, Rochester, Minnesota, USA., Abudayyeh A; Divison of Internal Medicine, Section of Nephrology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Anand S; Division of Nephrology, Stanford University School of Medicine, Palo Alto, California, USA., Glezerman I; Renal Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA., Motwani SS; Dana-Farber Cancer Institute Survivorship Program, Boston, Massachusetts, USA., Murakami N; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Wanchoo R; Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Hempstead, New York, USA., Ortiz-Melo DI; Division of Nephrology, Duke University School of Medicine, Durham, North Carolina, USA., Rashidi A; Division of Nephrology and Hypertension, University Hospital Cleveland Medical Center, Cleveland, Ohio, USA., Sprangers B; Department of Microbiology, Immunology and Transplantation, Laboratory of Molecular Immunology (Rega Institute for Medical Research), KU Leuven, Leuven, Belgium.; Division of Nephrology, University Hospitals Leuven, Leuven, Belgium., Aggarwal V; Department of Nephrology and Hypertension, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Malik AB; Division of Nephrology, University of Washington, Seattle, Washington, USA., Loew S; Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Berlin, Germany., Carlos CA; Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, California, USA., Chang WT; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Division of Cardiovascular Medicine, Chi-Mei Medical Center, Tainan, Taiwan.; Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan., Beckerman P; Institute of Nephrology and Hypertension, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Tel Aviv, Israel., Mithani Z; Katz Family Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA., Shah CV; Division of Nephrology, Hypertension, and Renal Transplant, Department of Medicine, University of Florida, Gainesville, Florida, USA., Renaghan AD; Division of Nephrology, University of Virginia Health System, Charlottesville, Virginia, USA., Seigneux S; Service of Nephrology, Department of Medicine, University Hospital of Geneva, Geneva, Switzerland., Campedel L; Department of Medical Oncology, Assistance Publique - Hopitaux de Paris, Paris, France., Kitchlu A; Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada., Shin DS; Division of Hematology-Oncology, VAGLAHS, Department of Medicine, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California, USA., Rangarajan S; Division of Hematology/Oncology and Division of Nephrology, The University of Alabama School of Medicine, Birmingham, Alabama, USA., Deshpande P; Division of Nephrology, Department of Medicine, Icahn School of Medicine at the Mount Sinai Hospital, New York, New York, USA., Coppock G; Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Eijgelsheim M; Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Gronigen, The Netherlands., Seethapathy H; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA., Lee MD; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA., Strohbehn IA; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA., Owen DH; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA., Husain M; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA., Garcia-Carro C; Nephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, Barcelona, Spain.; Nephrology Department, San Carlos Clinical University Hospital, Madrid, Spain., Bermejo S; Nephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, Barcelona, Spain., Lumlertgul N; Department of Critical Care & Nephrology, Guy's and St Thomas Hospital, London, UK.; Division of Nephrology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand., Seylanova N; Department of Critical Care & Nephrology, Guy's and St Thomas Hospital, London, UK.; Sechenov Biomedical Science and Technology Park, Sechenov First Moscow State Medical University, Moscow, Russian Federation., Flanders L; Department of Oncology, Guy's & St Thomas Hospital, London, UK., Isik B; Division of Nephrology & Hypertension, Mayo Clinic, Rochester, Minnesota, USA., Mamlouk O; Divison of Internal Medicine, Section of Nephrology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lin JS; Divison of Internal Medicine, Section of Nephrology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Garcia P; Division of Nephrology, Stanford University School of Medicine, Palo Alto, California, USA., Kaghazchi A; Division of Epidemiology and Population Health, Stanford University, Palo Alto, California, USA., Khanin Y; Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Hempstead, New York, USA., Kansal SK; Division of Nephrology and Hypertension, University Hospital Cleveland Medical Center, Cleveland, Ohio, USA., Wauters E; Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.; Department of Pneumology, University Hospitals Leuven, Leuven, Belgium., Chandra S; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA., Schmidt-Ott KM; Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Berlin, Germany.; Max Delbrück Center for Molecular Medicine, Helmholtz Association, Berlin, Germany., Hsu RK; Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, California, USA., Tio MC; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Sarvode Mothi S; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Singh H; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Schrag D; Division of Population Sciences, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Jhaveri KD; Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Hempstead, New York, USA., Reynolds KL; Division of Oncology, Massachusetts General Hospital, Boston, MA, USA., Cortazar FB; New York Nephrology Vasculitis and Glomerular Center, Albany, New York, USA., Leaf DE; Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Jazyk:	angličtina
Zdroj:	Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Oct; Vol. 9 (10).
DOI:	10.1136/jitc-2021-003467
Abstrakt:	Background: Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. Methods: We collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of ICPi-AKI and its recovery. A multivariable Cox model was used to estimate the effect of ICPi rechallenge versus no rechallenge on survival following ICPi-AKI. Results: ICPi-AKI occurred at a median of 16 weeks (IQR 8-32) following ICPi initiation. Lower baseline estimated glomerular filtration rate, proton pump inhibitor (PPI) use, and extrarenal immune-related adverse events (irAEs) were each associated with a higher risk of ICPi-AKI. Acute tubulointerstitial nephritis was the most common lesion on kidney biopsy (125/151 biopsied patients [82.7%]). Renal recovery occurred in 276 patients (64.3%) at a median of 7 weeks (IQR 3-10) following ICPi-AKI. Treatment with corticosteroids within 14 days following ICPi-AKI diagnosis was associated with higher odds of renal recovery (adjusted OR 2.64; 95% CI 1.58 to 4.41). Among patients treated with corticosteroids, early initiation of corticosteroids (within 3 days of ICPi-AKI) was associated with a higher odds of renal recovery compared with later initiation (more than 3 days following ICPi-AKI) (adjusted OR 2.09; 95% CI 1.16 to 3.79). Of 121 patients rechallenged, 20 (16.5%) developed recurrent ICPi-AKI. There was no difference in survival among patients rechallenged versus those not rechallenged following ICPi-AKI. Conclusions: Patients who developed ICPi-AKI were more likely to have impaired renal function at baseline, use a PPI, and have extrarenal irAEs. Two-thirds of patients had renal recovery following ICPi-AKI. Treatment with corticosteroids was associated with improved renal recovery. (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu